Besremi and Injection site extravasation - a phase IV clinical study of FDA data

Summary:

Injection site extravasation is reported as a side effect among people who take Besremi (ropeginterferon alfa-2b-njft), especially for people who are female, also take Aspirin, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Injection site extravasation when taking Besremi. It is created by eHealthMe based on reports of 2,586 people who have side effects when taking Besremi from the FDA, and is updated regularly.

What is Besremi?

Besremi has active ingredients of ropeginterferon alfa-2b-njft. eHealthMe is studying from 2,586 Besremi users. Check the latest studies of Besremi.

What is Injection site extravasation?

Injection site extravasation (flow of (blood or lymph) from injection site) is found to be associated with 556 drugs and 727 conditions by eHealthMe. Check the latest studies of Injection site extravasation.

On Jul, 15, 2026

2,586 people reported to have side effects when taking Besremi.
Among them, 17 people (0.66%) have Injection site extravasation.

Could Besremi cause Injection site extravasation?

Among these 17 people:

What is the gender of people who have Injection site extravasation when taking Besremi? *

female: 75 %
male: 25 %

What are other drugs people take besides Besremi? *

What are other side effects people have besides Injection site extravasation? *

Platelet Count Increased: 7 people, 41.18%
Abdominal Discomfort: 5 people, 29.41%
Hyperkalemia (damage to or disease of the kidney): 5 people, 29.41%
Fatigue (feeling of tiredness): 5 people, 29.41%
Dizziness: 5 people, 29.41%
Visual Impairment: 4 people, 23.53%
Hair Loss: 4 people, 23.53%
Haematocrit Increased: 4 people, 23.53%
Headache (pain in head): 4 people, 23.53%
Depressed Mood: 3 people, 17.65%

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 15 people, 88.24%
High Blood Pressure: 2 people, 11.76%
High Blood Cholesterol: 2 people, 11.76%
Essential Thrombocythaemia (chronic blood cancer): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Besremi and have Injection site extravasation?

- Check whether Injection site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Besremi:

Besremi (2,586 reports)

Browse all side effects of Besremi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site extravasation:

Injection site extravasation (556 drugs)

Browse all the conditions that are associated with Injection site extravasation:

Injection site extravasation (727 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ropeginterferon alfa-2b-njft (the active ingredients of Besremi) and Besremi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.